{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-143748","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2021-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.139174+00:00","generated_at":"2026-06-28T05:15:29.746096+00:00","sec_items":["1.01","1.02","2.01","2.03","3.02","5.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI closes Novitium buy for $89.5M cash + shares; $300M loan & $25M PIPE","bullets":["Consideration: $89.5M cash + 2.47M shares + up to $46.5M earn-out.","New financing: $300M Term Loan (Truist) + $40M revolver + $25M PIPE from Ampersand.","Appoints Novitium co-founders: Samy Shanmugam as Head of R&D/COO & director; Chad Gassert as SVP Corp Dev.","Pro-forma YTD Sep 30 revenue $202.5M; non-GAAP EBITDA $66.6M; immediately accretive to adj. EPS.","Novitium pipeline: 20+ launches in 18 months, 13 approvals since March 2021, including CGT products."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-143748","json":"https://secwatch.observer/filing/0001104659-21-143748.json","markdown":"https://secwatch.observer/filing/0001104659-21-143748.md","text":"https://secwatch.observer/filing/0001104659-21-143748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/0001104659-21-143748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:15:29.746096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57b98056b4","claim":"Muthusamy Shanmugam was appointed as Head of Research & Development and Chief Operating Officer–Novitium Operations at ANI PHARMACEUTICALS INC.","evidence_excerpt":"On the Closing Date, in connection with the consummation of the Acquisition, the Company announced the appointment of Muthusamy Shanmugam, age 54, as Head of Research & Development and Chief Operating Officer–Novitium Operations.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/0001104659-21-143748-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Head of Research & Development and Chief Operating Officer–Novitium Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}